Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron in Pediatric Subjects With Neurogenic Detrusor Overactivity (KANGUROO)
NCT05491525Phase 3Recruiting
- Sponsor
- Urovant Sciences
- Start
- Oct 2022
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label trial of vibegron in neurogenic detrusor overactivity (NDO) (3 cohorts), sponsored by Urovant Sciences. Primary endpoint: Maximum Cystometric Capacity at 24 weeks. Started Oct 2022; status: recruiting.
02
Drugs
vibegron
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT05491525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491525.